Healthcare Industry News: Janssen
News Release - October 30, 2007
NPS Pharmaceuticals Names Douglas N. Dobak Vice President of Regulatory Affairs and Drug SafetyBEDMINSTER, N.J., Oct. 30 (HSMN NewsFeed) -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) announced today the appointment of Douglas N. Dobak as vice president, regulatory affairs and drug safety. Mr. Dobak joins NPS from AstraZeneca where he served in various senior leadership positions within that company's global and U.S. regulatory affairs organizations. His most recent positions at AstraZeneca were executive director, U.S. regulatory affairs, and global vice president, regulatory affairs, respiratory and inflammation area. Previously, he held regulatory affairs positions with Pfizer, Janssen Pharmaceutical, SmithKline Beecham, DuPont Pharmaceuticals, and Bristol-Myers Squibb.
"Doug brings more than thirty years of experience supporting new drug approvals and product launches for many of the pharmaceutical industry's leading companies," said Dr. Francois Nader, executive vice president and chief operating officer of NPS, to whom Mr. Dobak will report. "His expertise in regulatory affairs and knowledge of multiple therapeutic areas, including gastrointestinal disorders, will be invaluable as we work to advance our late- stage product candidates, GATTEX and PREOS. In particular, Doug has played important roles in the approval and launch of Propulsid and Nexium and line extensions for Prilosec that will be helpful as we continue our work in the treatment of gastrointestinal disorders with GATTEX."
NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.
Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of October 30, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year- ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter- ended June 30, 2007.
Source: NPS Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.